(Press-News.org) Pumping over 100,000 times a day, the heart is a critical muscle needed to deliver oxygen and nutrients to our organs to sustain healthy bodily function. Unfortunately, heart failure affects an estimated 6.2 million people in the U.S. and a staggering 64 million worldwide.
Of older patients with heart failure and abnormally thickened hearts, as many as one in five have an underdiagnosed, highly progressive and fatal condition called transthyretin amyloid cardiomyopathy, or ATTR-CM. The disease, which can be hereditary or develop spontaneously, is defined by an accumulation of misfolded transthyretin (TTR) proteins in the heart. These protein deposits weaken the heart muscle and, over time, cause extreme restriction of heart function, leading to failure.
Patients with the most common form of ATTR-CM frequently face misdiagnosis in clinics due to limited disease knowledge and symptoms that resemble other more common heart-related conditions. Additionally, they contend with a scarcity of approved drugs, as the sole available treatment specifically indicated for the most common form of ATTR-CM costs about $225,000 per year and is not readily accessible.
Investigators for the ATTRibute-CM phase 3 trial report in the New England Journal of Medicine that the novel drug acoramidis showed promise against ATTR-CM and is safe. Their data show that acoramidis achieves near-complete stabilization of the TTR proteins, which may slow or halt disease progression. Based on the efficacy and safety data from this randomized, multicenter, controlled 30-month study, BridgeBio Pharma (Palo Alto, CA) is seeking approval from the Food and Drug Administration (FDA) for use in these patients.
“We hope that, when this drug receives approval from the FDA, it will create competition in the market and drive down the cost of these incredibly expensive medications,” said Daniel Judge, M.D., a cardiologist at the Medical University of South Carolina who is also an ATTRibute-CM investigator and co-leader of the trial’s steering committee.
Judge and his colleague, Isabella Graef, M.D., of Stanford University have dedicated years to researching and developing a novel treatment for these patients. Graef spearheaded the creation of the new drug targeting misfolded proteins central to the disease, and Judge has since been heavily involved in phase 2 and 3 clinical trials, testing the new drug in his clinic at MUSC. In fact, MUSC was one of the first sites in the world to enroll patients into the ATTRibute-CM phase 3 trial.
The ATTRibute-CM investigators found that acoramidis binds to circulating TTR protein, preventing it from depositing as amyloid. Compared with placebo, acoramidis reduced hospitalizations for heart-related events, decreased cardiac congestion as determined by blood tests and increased the distance walked over six minutes.
In data shown by Judge at the American Heart Association, the number of people needed to treat with acoramidis to prevent one cardiovascular hospitalization in one year during this study was five. Overall, treatment adverse events were low and similar in both the acoramidis and placebo groups, indicating that the drug is safe. These data hold great promise for ATTR-CM patients and suggest that acoramidis may halt disease progression and increase survival rates.
With over 20 years of practicing cardiology and specializing in translational research targeting heart disease, Judge has recruited and followed several patients involved with the acoramidis clinical trials. He and his co-investigators have witnessed the novel drug move through translational testing and have been able to see the direct benefit to real patients suffering with ATTR-CM.
“Early in my career, I was disappointed by the lack of any available treatments. I’m glad to see another successful trial for ATTR-CM,” said Judge. “A patient whom I first met in 2017 had a prognosis of three years. Fast forward to 6.5 years later, and this same patient, who was one of the first participants enrolled at MUSC in the phase 2 trial, seems to be getting better due to acoramidis.”
If the disease can be stabilized, the hope is that the heart can improve gradually. Safely and effectively halting disease progression with acoramidis could provide improved quantity and quality of life for patients worldwide suffering from ATTR-CM.
# # #
About MUSC
Founded in 1824 in Charleston, MUSC is the state’s only comprehensive academic health system, with a unique mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates more than 3,200 students in six colleges – Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy – and trains more than 900 residents and fellows in its health system. MUSC brought in more than $298 million in research funds in fiscal year 2022, leading the state overall in research funding. MUSC also leads the state in federal and National Institutes of Health funding, with more than $220 million. For information on academic programs, visit musc.edu.
As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. Patient care is provided at 16 hospitals (includes owned and equity stake), with approximately 2,700 beds and four additional hospital locations in development; more than 350 telehealth sites and connectivity to patients’ homes; and nearly 750 care locations situated in all regions of South Carolina. In 2022, for the eighth consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.
MUSC has a total enterprise annual operating budget of $5.1 billion. The nearly 26,000 MUSC family members include world-class faculty, physicians, specialty providers, scientists, students, affiliates and care team members who deliver groundbreaking education, research, and patient care.
END
CAMBRIDGE, MA — A key chemical reaction — in which the movement of protons between the surface of an electrode and an electrolyte drives an electric current — is a critical step in many energy technologies, including fuel cells and the electrolyzers used to produce hydrogen gas.
For the first time, MIT chemists have mapped out in detail how these proton-coupled electron transfers happen at an electrode surface. Their results could help researchers design more efficient fuel cells, batteries, or other energy technologies.
“Our advance in this paper was studying and understanding the nature of how these electrons and protons couple ...
Scientists are making significant strides in the development of ultrabroadband white laser sources, covering a wide spectrum from ultraviolet to far infrared. These lasers find applications in diverse fields such as large-scale imaging, femto-chemistry, telecommunications, laser spectroscopy, sensing, and ultrafast sciences.
However, the pursuit faces challenges, particularly in the selection of appropriate nonlinear mediums. Traditional solid materials, while efficient, are prone to optical damage under high peak power conditions. Gas mediums, though ...
A discovery from an experiment with magnets and lasers could be a boon to energy-efficient data storage.
“We wanted to study the physics of light-magnet interaction,” said Rahul Jangid, who led the data analysis for the project while earning his Ph.D. in materials science and engineering at UC Davis under associate professor Roopali Kukreja. “What happens when you hit a magnetic domain with very short pulses of laser light?”
Domains are areas within a magnet that flip from north to south poles. This property is used for ...
What makes a soldier switch sides? That is a really good question. Especially when the soldier is an antibody that is supposed to defend the body against one of the world's most dangerous snake venoms but instead ends up helping the venom kill the body.
The question has become topical after a group of DTU researchers slightly changed how they tested an antibody that had previously proven promising as an antidote to snake venom. In the first experiment on mice, the damaging effect on muscle tissue from the venom of Bothrops Asper, ...
Just like a book can’t be judged by its cover, a material can’t always be judged by its surface. But, for an elusive conjectured class of materials, physicists have now shown that the surface previously thought to be “featureless” holds an unmistakable signature that could lead to the first definitive observation.
Higher-order topological insulators, or HOTIs, have attracted attention for their ability to conduct electricity along one-dimensional lines on their surfaces, but this property is quite difficult to experimentally distinguish from other ...
Dr. Marcus D. Goncalves Inducted into the American Society for Clinical Investigation
Dr. Marcus D. Goncalves, the Ralph L. Nachman, M.D. Research Scholar and an assistant professor of medicine in the Division of Endocrinology, Diabetes and Metabolism at Weill Cornell Medicine, has been elected as a member of the American Society for Clinical Investigation (ASCI) for 2024.
The ASCI is one of the nation’s oldest nonprofit medical honor societies and focuses on the unique role of physician-scientists in research, clinical care and medical education. It is comprised of more than 3,000 physician-scientists representing ...
Many cancers, including some types of breast cancer, are driven by alterations in the activity of cellular enzymes called kinases. Therapies that directly inhibit these cancer-promoting activities have proven to be effective for patients in which individual driving kinases can be diagnosed.
One major challenge to this therapeutic approach is to accurately quantify tumor kinases in human biopsy samples. Many kinases are not abundantly present and are therefore more difficult to measure accurately. Although currently there are methods to quantify small amounts of kinases, measuring multiple kinases ...
As part of our open science strategy, Canadian Science Publishing (CSP) is pleased to announce our new partnership with OA Switchboard, a mission-driven, community led initiative designed to simplify the sharing of information between stakeholders about open access publications throughout the whole publication journey.
“We’re thrilled to partner with the OA Switchboard to improve the visibility of the work we publish,” says Elaine Stott, Chief Executive Officer of CSP. “This initiative enables institutions, consortia and funders to report ...
Sustainable water management is an increasing concern in arid regions around the world, and scientists and regulators are turning to remote sensing tools like OpenET to help track and manage water resources. OpenET uses publicly available data produced by NASA and USGS Landsat and other satellite systems to calculate evapotranspiration (ET), or the amount of water lost to the atmosphere through soil evaporation and plant transpiration, at the level of individual fields. This tool has the potential to revolutionize water management, allowing for field-scale ...
Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.
Affecting 1 in 10,000 females at birth, and males even more rarely, Rett syndrome is a rare genetic neurodevelopmental disorder that affects brain development.
“It robs affected individuals of the ability to use their hands or speak and causes problems with mobility, as well as a number of other issues,” said Jeffrey Neul, Annette Schaffer Eskind Professor, ...
